JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Larimar Therapeutics (NASDAQ:LRMR) and maintained a $25 price target.
March 12, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Larimar Therapeutics and maintained a $25 price target.
The reiteration of a Market Outperform rating and a maintained price target of $25 by a JMP Securities analyst suggests a strong bullish sentiment towards Larimar Therapeutics. This endorsement is likely to instill confidence in investors and could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100